Genelux has filed a notice of an exempt offering of securities to raise $33,304,319.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Genelux is raising $33,304,319.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Thomas Zindrick played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Genelux
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1, an animal health product candidate. It has a licensing agreement with ELIAS Animal Health, LLC. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.
To learn more about Genelux, visit http://genelux.com/
Contact:
Thomas Zindrick, Chief Executive Officer
805-267-9889
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.